Predictive Oncology (NASDAQ:POAI) Stock, Quote.Headers.trade-ideas

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

xr:d:DAFqNaIkdw0:2,j:153520640059868796,t:23073113

News

Intraday Update

Markets

Movers

Trading Ideas

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

COUR

CREV

DECK

DOUG

DXCM

EVRI

FWRD

GROM

KARO

KITT

LBRDA

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SGMO

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WINT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ASTS

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

LULU

PEGA

PLXS

RBBN

SHYF

SLGL

SLRX

STLA

TIVC

VKTX

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Medicine,Doctor,Touching,Electronic,Medical,Record,On,Tablet.,Dna.,Digital

Predictive Oncology shares are blasting higher Thursday after the company announced it is expanding its AI and machine learning driven drug discovery platform to pursue discovery of novel biomarkers. Here&#39;s a look at what&#39;s going on:

Why Predicitive Oncology Stock Is Soaring

Predictive Oncology Inc

Lead investors, Delta Air Lines, Inc.,&nbsp;CK&nbsp;Wheels&nbsp;LLC, and Cox&nbsp;Investment Holdings,&nbsp;LLC, agreed to extend the lock-up restriction with respect to all their shares of common stock&nbsp;issued under the Investment and Investor Rights Agreement, for an additional year, until September&nbsp;20,&nbsp;2025.
In addition, Kore Capital LLC and funds managed by Whitebox&nbsp;Advisors LLC, agreed to extend the lock-up restriction with respect to&nbsp;72.5%&nbsp;of their shares until September&nbsp;20,&nbsp;2025.

Wheels Up Says Approximately 97.2% Of Lead Investor Shares Will Remain Subject To The Lock-up Restriction Until September 20, 2025

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>), the world's trusted infrastructure consulting firm, today announced its selection by the City of Austin as the prime consultant for the expansion of the Walnut Creek Wastewater Treatment Plant (WWTP) in Austin, Texas. The project aims to improve the aging structure's operational and environmental features by increasing the plant's capacity from 75 million gallons per day (MGD) to 100 MGD. As the population of Austin grows, the upgrades will bolster the resiliency of the community's wastewater infrastructure while safeguarding its surrounding ecosystem.
"As our industry's leading Water consulting firm, we look forward to continuing our long-standing partnership with the City of Austin to ensure the Walnut Creek Expansion delivers state-of-the-art treatment capabilities to the local community," said Beverley Stinson, chief executive of AECOM's global Water business. "Our teams have established themselves as pioneers in the global push to advance highly efficient and cost effective nutrient removal, and will leverage this extensive expertise to enhance the plant and improve the effluent water quality to protect the environment, while meeting existing and future community demands."
The AECOM team's scope of work for the project includes process, mechanical, civil, electrical and structural engineering services to modernize and upgrade the existing infrastructure, while incorporating advanced operational and environmental features. The expansion will involve replacing aging equipment, constructing a new 25 MGD treatment train, and building a new 120-inch outfall line and structure. The project will also provide wet weather treatment with new 100 MGD cloth filters and build a flood wall to protect against 100-year floods in accordance with the National Weather Service's historic <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.austintexas.gov%2Fdepartment%2Fflood-risk-and-atlas-14&amp;esheet=54125161&amp;newsitemid=20240923628017&amp;lan=en-US&amp;anchor=Atlas+14&amp;index=1&amp;md5=f42d51c75c9b61534bc111d8082f631f">Atlas 14</a> flood risk study.
"AECOM has a longstanding partnership with the City of Austin, having designed substantial portions of the City's major water and wastewater treatment plants," said Matt Crane, chief executive of AECOM's U.S. West region. "Our expertise in complex treatment design will support an exceptionally resilient, sustainable facility, aligning with our Sustainable Legacies strategy to make a lasting positive impact through every project we undertake."
Originally built in 1977 with an 18 million gallon per day capacity, the Walnut Creek Wastewater Treatment Plant has since been expanded three times in 1987, 1990, and 2005 to reach its current capacity of 75 million gallons per day. The facility is expected to remain operational throughout the work.

AECOM to Lead Major Expansion of Austin's Walnut Creek Wastewater Plant, Boosting Capacity to 100 MGD

Tempur Sealy International, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>, ", Company", or ", Tempur Sealy", )))) today provided an update with respect to the Company's agreement to acquire Mattress Firm Group Inc. ("Mattress Firm"), which is currently being challenged in federal court by the Federal Trade Commission ("FTC").
The litigation process continues to progress, with hearings currently scheduled to begin on November 12, 2024, and expected to last two weeks. The Company continues to believe that a successful litigation process can be completed in the coming months, which would allow the transaction to close in late 2024 or early 2025, consistent with previous expectations.
In conjunction with the planned Mattress Firm acquisition, Tempur Sealy has entered into a purchase agreement with MW SO Holdings Company, LLC ("Mattress Warehouse"), a leading independently owned bedding specialty retailer, for the sale of 73 Mattress Firm retail locations and the Company's Sleep Outfitters subsidiary, which includes 103 specialty mattress retail locations and seven distribution centers.
Mattress Warehouse is a multi-branded retailer offering a full array of mattresses at various price points. Tempur Sealy will continue to supply its Tempur-Pedic, Stearns &amp; Foster, and Sealy products to the divested Mattress Firm and Sleep Outfitters stores. The divestiture is subject to the closing of Tempur Sealy's acquisition of Mattress Firm and other customary closing conditions. It is expected to close approximately one quarter after the closing of the Mattress Firm transaction.
Company Chairman and CEO Scott Thompson commented, "As part of our engagement with the FTC on the proposed acquisition of Mattress Firm, we conducted a divestiture process, which led to an agreement with Mattress Warehouse, a company with extensive mattress retail experience, a strong capital base, and a capable leadership team."

Government

Regulations

Tempur Sealy Moves Forward with Mattress Firm Acquisition, FTC Court Hearings Set for November

Tempur Sealy intends to use the proceeds from the Term Loan B, together with cash available and proceeds from other debt, to fund the cash consideration for the previously announced acquisition of Mattress Firm Group Inc.. Tempur Sealy intends to draw on the Term Loan B concurrent with the closing of the Mattress Firm acquisition.

Tempur Sealy Launches Proposed Senior Secured Term Loan B Facility In An Aggregate Principal Amount Of Up To $1.6B

Keybanc analyst Jackson Ader maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $300 to $345.

Price Target

Analyst Ratings

CRWD

Keybanc Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $345

Keybanc analyst Sangita Jain maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $230 to $265.

Keybanc Maintains Overweight on Constellation Energy, Raises Price Target to $265

Keybanc analyst Steve Barger maintains Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) with a Overweight and raises the price target from $215 to $245.

Keybanc Maintains Overweight on Applied Industrial Techs, Raises Price Target to $245

The&nbsp;Committee for Medicinal Products for Human Use (CHMP)&nbsp;of the European Medicines Agency based its positive opinion on results from the MANDARA Phase III trial published in&nbsp;The New England Journal of Medicine, which compared the efficacy and safety of&nbsp;Fasenra&nbsp;to the only approved EGPA treatment, mepolizumab, in patients with relapsing or refractory EGPA.
MANDARA was the first head-to-head non-inferiority trial of biologics in patients with EGPA. Patients were randomized to receive either a single 30 mg subcutaneous injection of&nbsp;Fasenra, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks.

Biotech

Large Cap

Health Care

General

AstraZeneca's Fasenra (Benralizumab) Has Been Recommended For Approval In The European Union As An Add-on Treatment For Adult Patients With Relapsing Or Refractory Eosinophilic Granulomatosis With Polyangiitis

SpaceX CEO Elon Musk said on Monday that there are <a href="https://www.benzinga.com/news/24/09/40967983/spacex-pushes-ahead-with-fifth-starship-test-flight-preparation-despite-no-faa-launch-approvals-in-s">multiple regulatory hurdles</a> to launching a rocket, including getting clearance from the U.S. Fish and Wildlife Service.
What Happened: &#8220;We need multiple Fish licenses to launch a rocket (actually)!,&#8221; Musk wrote on social media platform X, referring to clearance from the United States Fish and Wildlife Service required ahead of space missions confirming that the operations will not impact surrounding wildlife.
The CEO was responding to a snippet of his interview with Lex Fridman from November 2023 where he said, &#8220;Currently, the limiting factor for SpaceX, for Starship launch, is regulatory approval.&#8221;
&#8220;I don&#8217;t think the public is quite aware of the madness that goes on,&#8221; Musk then said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We need multiple Fish licenses to launch a rocket (actually)! <a href="https://t.co/K9zj0EqyTZ">https://t.co/K9zj0EqyTZ</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1838089797224497250?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Earlier this month, SpaceX said in a blog post that the delay in getting regulatory approvals for the fifth test flight of its ambitious Starship, despite the launch vehicle being ready, is because the Federal Aviation Administration is consulting with the U.S. Fish and Wildlife on the impact of the proposed flight on surrounding wildlife, among other reasons. 
On Sunday, Musk also raised concerns about the Starship program getting &#8220;smothered&#8221; by government bureaucracy. The bureaucracy is rising and the regulatory red tape is affecting all large projects in America, the CEO said. 
The regulations, Musk previously said, <a href="https://www.benzinga.com/news/24/09/40812203/elon-musk-warns-spacexs-efforts-to-make-life-multiplanetary-would-be-effectively-illegal-without-maj">will intensify </a>if Kamala Harris is elected President in the upcoming elections. While Republican Donald Trump has expressed willingness to initiate a government efficiency commission aimed at reducing regulations, the red tape would only rise under a Democratic party administration, Musk opined.
Why It Matters: Musk on Sunday also said that SpaceX intends to launch about five uncrewed Starships to Mars in two years, elaborating on his timeline from earlier this month.
If the five uncrewed missions land safely, crewed missions will be&nbsp;<a href="https://www.benzinga.com/news/24/09/40972893/trumps-mars-landing-promise-gets-slammed-by-peter-schiff-even-as-elon-musk-says-spacex-plans-5-launc" target="_blank" rel="noreferrer noopener">possible in four years</a>, Musk said. However, in case of challenges, the crewed missions will be postponed another two years, he added, pegging crewed Starship missions to Mars for as early as 2028 and latest by 2030.
However, the Starship has undergone only four test flights to date, and Musk has previously made tall claims about the Starship&#8217;s readiness. Musk aims to take humans to Earth&#8217;s orbit, the Moon, and Mars with the spacecraft. 
However, Musk&#8217;s SpaceX has been increasing its launch frequency with its Falcon launch vehicles alone. Earlier this month, the company launched its <a href="https://www.benzinga.com/news/24/09/40916098/elon-musks-spacex-launches-90th-mission-in-2024-with-over-a-third-of-launch-target-still-to-go">90th mission for the year</a> with its Falcon 9 workhorse accounting for a majority of the launches. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="ttps://www.benzinga.com/news/24/09/40973892/unifor-members-at-gms-cami-assembly-and-battery-assemble-plants-secure-new-contract-with-pay-increas">Unifor Members At GM&#8217;s CAMI Assembly And Battery Assemble Plants Secure New Contract With Pay Increases</a></li>
</ul>
Image Via Shutterstock

SPACE

Tech

Elon Musk Shares It Takes 'Multiple Fish Licenses' To Launch A Rocket: 'I Don't Think The Public Is Quite Aware Of The Madness That Goes On,' Says SpaceX CEO

<a href="https://americanbatterytechnology.com/">&nbsp;American Battery Technology Company</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>), an integrated critical battery materials company that is commercializing its technologies for both primary battery minerals manufacturing and secondary minerals lithium-ion battery recycling, has been <a href="https://www.energy.gov/mesc/bipartisan-infrastructure-law-battery-materials-processing-and-battery-manufacturing-recycling">selected for a highly competitive grant for $150 million</a> dollars of federal investment&nbsp;by the U.S. Department of Energy to be applied towards the construction of a new lithium-ion battery recycling facility.
&nbsp;
This facility will be the company's second commercial-scale lithium-ion battery recycling facility and is designed to process approximately 100,000 tonnes of battery materials per year from its battery manufacturer, automotive OEM, and community partners.
"We are extremely honored to be selected for this government investment to further expand our domestic battery recycling operations, and after having gone through nearly one-year of technical and economic evaluation, we appreciate the level of diligence that the government employed in making this decision," stated ABTC CEO Ryan Melsert. "We are greatly appreciative of the confidence and support we have received from our partners throughout this process and are energized to move forward with our feedstock supply, product offtake, and strategic stakeholders in this critical expansion of our domestic capabilities."
True to the company's strategic model to engage a diverse portfolio of partners and stakeholders to bring advanced battery technologies online and establish a commercial battery metals supply chain for North America, this project will leverage multiple partners including feedstock supplier and critical mineral product offtaker BASF, global engineering firm Siemens, the Clemson University International Center for Automotive Research (CU-ICAR), the Argonne National Laboratory (ANL) ReCell Center, the Argonne National Laboratory Sustainable Transportation Education &amp; Partnerships (STEP) department, and the South Carolina Electric Transportation Network (SCETNetwork). &nbsp;
ABTC constructed and commissioned its first lithium-ion battery recycling facility near Reno, Nevada in Fall 2023, which implements its internally-developed processes for the strategic de-manufacturing and targeted chemical extraction of battery materials in order to manufacture battery grade products at competitive costs and with low environmental footprint.&nbsp; These processes are fundamentally different than conventional methods of battery recycling, which generally utilize either high temperature smelting or non-strategic shredding systems.
Through this new facility construction project, ABTC will employ a proactive, community-driven engagement model to build an energy equity, sustainable circular manufacturing ecosystem that aims to create 1,200 construction jobs and 300 operations jobs. The company will work in direct partnership between communities, educational institutions, industry, government, the National Laboratory system, and the next generation workforce to support equitable and sustainable initiatives that benefit and strengthen in local communities, including in underserved communities that have historically been left behind.
ABTC is partnering with government entities and local educational institutions, such as ANL's STEP department and Clemson University, to create career pathways in battery recycling and establish a talent pipeline for the domestic battery recycling industry.
Bringing first-of-kind technologies to market,&nbsp;ABTC's battery recycling and primary battery metals commercialization efforts support the buildout of a domestically-sourced battery metals circular supply chain.&nbsp; ABTC has been selected for several competitive awards supporting the advancement and commercialization of its first-of-kind technologies for both battery recycling and primary claystone-to-lithium hydroxide manufacturing.&nbsp; &nbsp; U.S. DOE Investments in ABTC Lithium-Ion Battery Recycling&nbsp;
<ul>
<li>October 2021: ABTC was awarded a competitive grant for a <a href="https://americanbatterytechnology.com/projects/usabc-project/">$2 million project</a> from the United States Advanced Battery Consortium (USABC) supported by funding from US DOE to foster the recycling of battery packs and extraction of battery metals, with USABC cost contributions of $500k.</li>
<li>November 2022: <a href="https://americanbatterytechnology.com/press-release/american-battery-technology-company-receives-contract-from-us-doe-for-20m-project-to-accelerate-commercialization-of-next-generation-advanced-battery-recycling-technologies/">ABTC was awarded for a competitive grant for a $20 million project from the U.S. DOE to scale</a>, optimize, and commercialize three next generation technologies to even further enhance the performance of its recycling operations, with a federal contribution of $10 million.</li>
<li>March 2024:<a href="https://americanbatterytechnology.com/press-release/american-battery-technology-company-awarded-20-million-tax-credit-through-competitive-us-doe-process-to-advance-its-critical-minerals-battery-recycling-facility/"> ABTC awarded qualifying advanced energy project tax credits (48C) for $20 million</a> to be applied towards capital expenditures of its first battery recycling facility near Reno, Nevada.</li>
<li>March 2024: <a href="https://americanbatterytechnology.com/press-release/american-battery-technology-company-awarded-additional-40-million-competitive-tax-credit-to-accelerate-construction-of-next-battery-recycling-facility/">ABTC awarded qualifying advanced energy project tax credits (48C) for $40 million</a> to be applied towards capital expenditures of its second battery recycling facility.</li>
<li>TBD 2025: <a href="https://americanbatterytechnology.com/press-release/american-battery-technology-company-receives-contract-from-us-doe-for-20m-project-to-accelerate-commercialization-of-next-generation-advanced-battery-recycling-technologies/">ABTC was selected for this competitive grant for a $150 million project from the U.S. DOE to construct a second battery recycling facility</a>.</li>
</ul>
U.S. DOE Investments in ABTC Lithium Hydroxide (LiOH) from Claystone Manufacturing&nbsp;
<ul>
<li>October 2021: <a href="https://www.energy.gov/eere/ammto/advanced-manufacturing-office-fy20-critical-materials-foa-selections">ABTC was awarded a competitive grant supporting a $4.5 million project</a> from the U.S. DOE for the demonstration of its battery-grade lithium hydroxide production from Nevada claystone resources, with federal contributions of $2.27 million.</li>
<li>October 2022: <a href="https://americanbatterytechnology.com/press-release/american-battery-technology-company-receives-contract-for-57m-grant-from-us-doe-for-construction-of-commercial-scale-lithium-hydroxide-refinery/">ABTC was awarded a competitive grant supporting a $115 million project</a> from the U.S. DOE to construct a commercial-scale lithium hydroxide refinery, with a federal contribution of $57.7 million.</li>
</ul>
These battery recycling technologies were developed in-house by the ABTC R&amp;D, project management, and engineering team members, many of whom were previously members of the founding Tesla Gigafactory design and engineering teams. &nbsp;ABTC intends to utilize these significant experiences in collaboration with project partners to scale processes and bring first-of-kind commercial-scale facilities online and leveraging this expertise to de-risk ABTC's commercialization of this second battery recycling facility.
As ABTC has now completed the technical and economic evaluations and been selected for this competitive grant award, it will next enter the grant award contracting phase of this process with an expected project kickoff in 2025.

ABAT

American Battery Technology Secures $150M US DOE Grant, Expanding Battery Recycling Facility

Management

Owens & Minor Has Appointed Jonathan Leon As Executive Vice President And Chief Financial Officer, Effective Immediately

Lifezone Metals Limited's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) Chief Executive Officer, Chris Showalter, is pleased to announce that Lifezone, in partnership with BHP, has formally commenced the project financing process for the Kabanga Nickel Project in Tanzania. In conjunction, Lifezone has received a Letter of Interest from the U.S. International Development Finance Corporation (DFC) that expressed DFC's interest in considering the Project for loans as part of the Project's financing package.
Tanzanian Minister of Minerals, Hon. Anthony Mavunde, welcomed the news, saying: "The Kabanga Nickel Project is a model example of the Government of Tanzania's commitment to fostering sustainable development and economic growth for the benefit of Tanzania and Tanzanians. We are delighted with the announcement that DFC has signed a Letter of Interest for project finance of Kabanga. Building on the 2023 visit to Tanzania by Vice President Harris, DFC's action shows that Tanzania and the United States continue to develop a strong economic partnership founded on a shared vision for sustainable development and we are looking forward to further developing our relationship to pursue our common goals. This project will not only boost our economy regionally and nationally, but also position Tanzania as a leading international player in the global nickel market, contributing significantly to the global energy transition."
Mr. Showalter also commented: "The initiation of the project financing process with Societe Generale is a crucial next step in securing the funding required for Kabanga, and is yet another indicator of the strategic importance of the Project to our global partners. With DFC's interest in supporting Kabanga, the U.S. government clearly recognizes the critical role that sustainable mineral development in Africa plays in the global energy transition. Today's announcement reinforces this vision and again highlights the strong relationship between the United States and Tanzania."
Scott Nathan, Chief Executive Officer of DFC added: "DFC is helping to advance the global energy transition through projects that drive sustainable development and economic growth. The Kabanga Nickel Project represents a significant opportunity to advance responsible mineral development in Tanzania, diversifying critical supply chains and fostering economic resilience in the region."
The DFC loan application would initiate a comprehensive review process; this follows <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lifezonemetals.com%2Fnews%2Fpress-releases%2Fnews-details%2F2024%2FLifezone-Metals-Initiates-Process-for-Risk-Insurance-with-U.S.-International-Development-Finance-Corporation-for-the-Kabanga-Nickel-Project-in-Tanzania%2Fdefault.aspx&amp;esheet=54125613&amp;newsitemid=20240923733638&amp;lan=en-US&amp;anchor=Lifezone%26%238217%3Bs+August+27%2C+2024+announcement&amp;index=1&amp;md5=f757042432b47c95de66350df5fb940b">Lifezone's August 27, 2024 announcement</a> that DFC would be evaluating political risk insurance coverage for future investments in Kabanga.
Kabanga is one of the world's largest and highest-grade undeveloped nickel sulfide deposits. By utilizing Lifezone's Hydromet technology, the project is expected to significantly reduce emissions compared to traditional smelting methods.
Kabanga is supported by the Partnership of Global Infrastructure and Investment (PGI), which is a values-driven, high-impact, and transparent infrastructure partnership that was created to meet the enormous infrastructure needs of low- and middle-income countries and to support the United States' and its allies' economic and national security interests. Kabanga is also recognized as a project within the Minerals Security Partnership, a collaboration of 14 countries and the EU to catalyze public and private investment in responsible critical minerals supply chains globally.
DFC is America's development finance institution. It partners with the private sector to finance solutions to the most critical challenges facing the developing world today across sectors including energy, infrastructure, healthcare, agriculture, and financial services. DFC investments adhere to high standards and respect the environment, human rights, and worker rights.
Societe Generale appointed as lead financial advisor to Kabanga Nickel Limited
Societe Generale has been appointed as the lead financial advisor to Kabanga Nickel Limited, a subsidiary of Lifezone that is managed by Lifezone and in which BHP has a 17% interest.
Lenaig Trenaux, Global Head of Batteries, Mining and Industries, Societe Generale, commented: "Societe Generale supports its clients in the energy transition, through dedicated solutions, and a commitment to contribute to sustainable finance. We are very pleased to be working jointly with Lifezone Metals and BHP to deliver the Kabanga Nickel Project, aiming to foster development in Tanzania and feed the energy transition with a large volume of low carbon critical mineral."
Societe Generale brings world-leading expertise in large-scale debt financing for mining projects globally. In cooperation with BHP, Lifezone and Societe Generale will look to optimize Kabanga's capital structure through a combination of multi-source project-level debt and equity.

Lifezone Metals and BHP Begin Project Financing for Tanzania's Kabanga Nickel, Supported by US DFC

Benchmark analyst Cody Acree reiterates Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Hold.

Reiteration

INTC

Benchmark Reiterates Hold on Intel

Needham analyst Mike Cikos reiterates Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Buy and maintains $28 price target.

CFLT

Needham Reiterates Buy on Confluent, Maintains $28 Price Target

Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (together with its subsidiaries, "IREN") today provided a business update. &nbsp;
"We are pleased to announce that we've reached our 20 EH/s milestone ahead of schedule. This achievement reflects the hard work of our global team. Thank you for your dedication and efforts in making this happen," said Daniel Roberts, Co-Founder and Co-CEO of IREN. "We look forward to continuing this momentum as we expand to over 30 EH/s in the next three months."
IREN achieves 20 EH/s milestone
IREN has increased its installed capacity to 20 EH/s (16 J/TH efficiency).
Through optimization of its existing data center infrastructure, IREN now expects to increase its installed capacity to 21 EH/s in the coming days.
On track for 31 EH/s in 4Q 2024
Childress Phase 3 (150MW) construction is well underway, with approximately 430 people mobilized to site.
As part of the expansion from 21 EH/s to 31 EH/s, previously purchased Bitmain S21 XP miners (13.5 J/TH) are scheduled for shipping over the next 2 months.
Based on 31 EH/s (15 J/TH efficiency):
<ul>
<li>$20k electricity cost per Bitcoin mined</li>
<li>$30k all-in cash cost per Bitcoin mined</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

IREN

Iris Energy Boosts Capacity to 20 EH/s, 31 EH/s Expected by End of 2024

TD Cowen analyst Oliver Chen downgrades Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Buy to Hold and announces $395 price target.

Downgrades

ULTA

TD Cowen Downgrades Ulta Beauty to Hold, Announces $395 Price Target

On September 20, 2024 the Board of Directors declared a quarterly cash dividend of 25.0 cents per share on the Company's common stock. The Board of Directors also approved a one-time special dividend of $2.50 per share.&nbsp;

Dividends

Ennis, Inc Declares $0.25 Quarterly Dividend, Approves Special $2.50 Payout

Strategic Synergies
The integration of Swifty is expected to bring several operational advantages and new revenue opportunities for Signing Day Sports:
<ul>
<li>Cost Efficiency: Swifty's in-house engineering team is expected to reduce Signing Day Sports' operating costs by over 50%, enabling the company to reinvest those savings into growth initiatives. It is also expected to increase the speed at which Signing Day Sports can roll out new products and technological enhancements to its current offering and optimize monetization of the product and user base.</li>
<li>Revenue Growth in SaaS: At their core, both Signing Day Sports and Swifty are SaaS model businesses. Swifty's scalability, technological resources, and technology initiatives are expected to bolster the growth of Signing Day Sports' app user base, enhance user retention and provide additional opportunities to monetize renewing subscribers with additional revenue streams.</li>
<li>New Revenue Streams: Swifty is expected to further expand Signing Day Sports' current product offering while also broadening the Company's exposure to new sports and athletes outside the U.S. Signing Day Sports has accumulated more than 10,000 registered users, which it plans to increase at an accelerated rate in the fourth quarter of 2024 and 2025. The Company's focus is to develop new strategic revenue streams, and improve revenue metrics per user, with the same aim of fully monetizing this growing user base.</li>
<li>New Market Exposure: Since its beginning as a football student-athlete recruitment platform provider, Signing Day Sports has expanded its platform to support baseball, softball, and men's and women's soccer. Swifty is expected to bring exposure to new markets in Europe, Africa and the Middle East, as well as exposure to emerging sports without established recruitment models. The Company anticipates that early adopters in these emerging sports markets are a significant market and plans to broaden its platform to capitalize on these prospective revenue streams.</li>
<li>Enhanced User Engagement: Swifty's team is expected to introduce exciting new features to Signing Day Sports, including gamification elements such as live scoreboards, top competitor leaderboards, fantasy leagues and real-time performance tracking, which are designed to boost engagement, organic user acquisition and user retention.</li>
</ul>

Signing Day Sports Provided An Update Regarding Its Financial Position And Its Plans To Acquire Dear Cashmere, Doing Business As Swifty Global, Highlighting The Strategic And Financial Synergies That Are Expected To Drive Accelerated Growth And Operational Efficiency For Both Companies

XOMA

ZVRA

XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones

Earnings

Earnings Misses

Ennis Q2 2024 GAAP EPS $0.40 Misses $0.42 Estimate, Sales $99.038M Miss $104.580M Estimate

Predictive Oncology, Augmedix, Cue Health among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When does a growth stock become one of the top <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to avoid?



It sounds like the beginning of a riddle or a bad joke, but the answer is obvious &ndash; it&rsquo;s when the stock is deceptive and tricks you into believing that it can be a good buy. You look at the Portfolio Grader and get interested because a stock has a good grade specifically for growth, but then realize that it still has an &ldquo;F&rdquo; rating overall.



How can that happen?



The Portfolio Grader rates stocks based on earnings history, growth, analyst sentiment and momentum. The growth grade in particular is a popular metric for finding growth stocks to avoid.



But it&rsquo;s also important to see why a company is getting a good growth grade. Because sometimes, looking at a single factor like growth can be misleading and can&rsquo;t make up for the company&rsquo;s deficiencies in other areas.



Today, we&rsquo;re going to look at several companies that have good growth grades, and we&rsquo;ll investigate why that&rsquo;s happening in each case. But then we&rsquo;ll pull back the curtain, look at the fuller picture, and explore why these growth stocks to avoid are still getting &ldquo;F&rdquo; grades overall.



In the end, an exercise like this is a good reminder to not rely on any one metric when considering your stock portfolio. Growth is highly desirable, but the growth stocks to avoid on this list can easily drag your portfolio into the gutter.



<h2>Virgin Galactic (SPCE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/spce1600-300x169.jpg" alt="Virgin Galactic (SPCE) billboard on the New York Stock Exchange, across from the Fearless Girl statue. aerospace stocks"><div>Source: Tun Pichitanon / Shutterstock.com</div></div>It makes sense to jump right into one of the growth stocks to avoid that&rsquo;s been a huge disappointment &ndash; and has cost plenty of investors a lot of money along the way. 



Virgin Galactic (NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/">SPCE</a>) made its name in the billionaire space race as founder Richard Branson competed with SpaceX and Blue Orgin to see which would be the first to make it into space with a civilian crew. 



You may remember that Virgin Galactic won that race, as it shot Branson into suborbital flight just a few days before Jeff Bezos did the same on a Blue Orgin rocket.



But honestly, that&rsquo;s the high point for this company. Space tourism doesn&rsquo;t feel any closer today than it did several years ago, and few people have the several hundred thousand dollars it takes to make the trip, even if the flights become a reality.



Virgin Galactic has burned through more than $1 billion in the last two years and rewarded investors with a 93% fall in stock price. SPCE recently completed a <a href="https://investorplace.com/2024/06/will-a-1-for-20-reverse-split-save-virgin-galactic-spce-stock/">1-for-20 reverse stock split</a> to push the price back over the Nasdaq threshold and maintain listing compliance, but the reality is that this is a bad stock and a weak company.



SPCE stock shows an &ldquo;A&rdquo; rating for growth in the Portfolio Grader because its revenue was up 410% in the last quarter. But sales of only $1.99 million show that people aren&rsquo;t lining up to ride a <a href="https://seekingalpha.com/article/4690417-virgin-galactic-holdings-inc-spce-q1-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A2">Delta rocket</a> into space as early as 2026, which is the company&rsquo;s latest projections.



SPCE stock gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Helius Medical Technologies (HSDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/tech1600a-300x169.jpg" alt="Image of hand touching globe with a city in the background, implying connectivity"><div>Source: Shutterstock</div></div>Helius Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) is a neurotech company headquartered in eastern Pennsylvania. The company makes medical devices that help people with balance and gait issues without getting a neurological implant. It is also one of the growth stocks to avoid in the space.



The company&rsquo;s devices improve the brain&rsquo;s ability to compensate for deficiencies and rehabilitate lost brain function. For instance, its Portable Neuromodulation Stimulator stimulates the brain through nerves in the tongue. 



It&rsquo;s being used as a short-term treatment to help people with multiple sclerosis symptoms. But it&rsquo;s an expensive device, priced at more than $23,000.



The company saw <a href="https://ir.heliusmedical.com/news-releases/news-release-details/helius-medical-technologies-inc-reports-first-quarter-2024">revenue grow</a> in the first quarter, giving it a decent growth grade in the Portfolio Grader. But we&rsquo;re still not looking at a lot of money. Revenue in the first quarter was $135,000, versus $111,000 in the same quarter a year ago.



It posted a net loss of $2.5 million, the same as a year ago. The earnings per share loss of $3.08 was better than the loss of $4.22 per share from Q1 2023.



HSDT stock is down 87% this year. It has an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>InMed Pharmaceuticals (INM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-1-1-300x169.jpg" alt="cannabis stocks"><div>Source: Shutterstock</div></div>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) is a Canadian company that is a clinical-stage pharmaceutical company that&rsquo;s working to develop cannabis-infused treatments for Alzheimer&rsquo;s disease, vision and skin conditions.



The company is attempting to develop an effective pipeline of drug candidates targeting CB1 and CB2 receptors. 



Its attempt to develop an anti-itch skin cream is in Phase 2 testing, and it is seeking a partnership to help it develop the product. Its other pipeline candidates for Alzheimer&rsquo;s and dry age-related macular degeneration are in preclinical trials.



Developing new therapies is an expensive undertaking and a challenge for investors because the company has to spend a lot of cash on research and development without seeing income for years, if ever.



For the third fiscal quarter of 2024 (ending March 31), InMed reported a net loss of $5.7 million. The company saw sales of $1.1 million, up slightly from a year ago, and a gross profit of $289,000, which was better than its profit of $192,511 in the same quarter a year ago.



The profit increase helps InMed&rsquo;s growth grade in the Portfolio Grader. Still, the company also acknowledges that it has money only to finance research and development into the fourth calendar quarter of 2024. That is a worrisome disclosure.



INM stock gets a &ldquo;B&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 36% this year.



<h2>P3 Health Partners (PIII)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>P3 Health Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/piii-stock-quote/">PIII</a>) is a health management company that supports providers with administrative services and coordination for their Medicare Advantage patients.



The company currently operates in Arizona, Oregon, Nevada, Florida and California, with a network of more than 2,900 primary care providers.



It recently announced raising <a href="https://ir.p3hp.org/news-events/press-releases/detail/106/p3-health-partners-inc-announces-approximately-42-2">$42.2 million</a> through the sale of 67.4 million units of stock with institutional investors, valued at just over 62 cents per share. That will give the company an infusion of cash to operate, but it also serves to dilute the share base.



First-quarter financial results included $388.5 million in revenue, up 29% from a year ago. But gross profits fell from $16.5 million to $6.4 million, and the company reported a net loss of $49.6 million.



PIII is among the growth stocks to avoid in part because it is down 62% this year. It gets an &ldquo;A&rdquo; rating for growth, but still has an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Sunshine Biopharma (SBFM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) is a Florida-based biopharma company developing potential treatments in oncology and antivirals.



Thanks to its ownership of a Canadian pharmacy, Nora Pharma, which distributes generic medications, Sunshine was able to show <a href="https://sunshinebiopharma.com/wp-content/uploads/20240521_SBFM-Press-Release-Reports-Q1_2024_.pdf">sales</a> of $7.5 million in the first quarter, a gain from $4.8 million a year ago. That gives it a solid grade for growth in the Portfolio Grader.



However, Sunshine is a long path to ever bringing its own drugs to market, and that&rsquo;s where the real money is made. Sunshine is currently testing a Covid-19 treatment in mice at the University of Arizona in hopes of developing a treatment for patients who cannot use Paxlovid, Molnupiravir or Remdisivir.



It has a second drug candidate, to treat cancer, ready for testing on mice as well. However, the company&rsquo;s third drug candidate, also a cancer drug, is on hold after lab tests did not yield a favorable result.



The Nora Pharma sales weren&rsquo;t enough to help Sunshine generate a profit for the quarter, either. It posted a net loss of $1.2 million versus a loss of $1.7 million in the first quarter of 2023.



SBFM stock is down 98% this year. It gets an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>MicroVision (MVIS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/mvis1600-300x169.png" alt="Autonomous Self Driving Car Moving Through highway - Animated Scanning Visualization Concept of Artificial Intelligence Digitalizes and Analyzes Road Using Lidar. MVIS stock"><div>Source: aslysun / Shutterstock.com</div></div>With more vehicles on the road these days than ever, the advances in driver-assisted technology are pretty interesting. MicroVision (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/">MVIS</a>) makes automotive lidar sensors to help driver-assistance systems and autonomous vehicles function.



The company&rsquo;s sensors are also used in industrial, smart infrastructure and robotics.



It gets a good grade for growth in the Portfolio Grader because the company increased its revenue in the first quarter, bringing in $956,000 versus $782,000 in the first quarter of 2023. That&rsquo;s a healthy percentage increase that helps give it an &ldquo;A&rdquo; grade for growth.



But then look closer. MicroVision lost <a href="https://ir.microvision.com/news/press-releases/detail/402/microvision-announces-first-quarter-2024-results">$26.3 million in the quarter</a>, versus a loss of $19 million in the same quarter a year ago. When you&rsquo;re losing that much money, an $174,000 increase in revenue doesn&rsquo;t help that much.



MVIS stock is down 59% this year. Despite its &ldquo;A&rdquo; grade for growth, MicroVision gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Predictive Oncology (POAI)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1-300x169.jpg" alt="A concept image representing AI (artificial intelligence)."></a>Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) is working to harness the power of artificial intelligence to help bring drugs to market. The company believes that AI can help reduce the time it takes to successfully test and manufacture a drug, and is working specifically on cancer therapies.



The company has a biobank of&nbsp;<a href="https://predictive-oncology.com/biobankai/">150,000 tumor tissue samples</a>&nbsp;and uses machine learning to help it test and discover successful molecules. It also uses AI for drug development and for clinical trials.



And it saw an uptick in revenue in the first quarter, bringing in $419,000 versus $239,000 in the first quarter of 2023.



But the company also posted a loss of $4.2 million and $1.04 per share, versus a loss of $3.4 million and 86 cents per share in the same quarter a year ago.



That&rsquo;s why POAI stock is getting an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 67% this year.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-growth-stocks-to-avoid-right-now-june-2024/">7 F-Rated Growth Stocks to Avoid Right Now: June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Right Now: June 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Shares of biotechnology specialist Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) &mdash; which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols &mdash; soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer. Therefore, POAI stock jumped higher on the credibility boost.



According to the biotech firm&rsquo;s <a href="https://finance.yahoo.com/news/predictive-oncology-enters-biomarker-discovery-110000330.html">press release</a>, a retrospective ovarian cancer study with UPMC Magee-Womens Hospital (based in Pittsburgh, Pennsylvania) demonstrated that Predictive&rsquo;s ML models can more accurately forecast short-term and long-term survival outcomes compared to clinical data alone.



Fundamentally, this development has brought much excitement to POAI stock because Predictive&rsquo;s deep learning protocol &mdash; combined with a diverse biobank of patient samples &mdash; may help accelerate biomarker discovery tied to patient survival and therapeutic response.



In addition, the underlying technology can act as a force multiplier, advancing the development of clinical support tools. The innovation may also allow for more efficient screening for clinical trial enrollment.



<h2>Massive Addressable Market Bodes Well for POAI Stock</h2>



Beyond the clinical implications, POAI stock soared on the underlying massive total addressable market. According to the release, the biomarker discovery market may end up with a valuation of $51.5 billion by year&rsquo;s end. Right now, the market capitalization of Predictive sits at $7.14 million.



Further, the sector might only expand from here on out. Data from Grand View Research states that the global biomarker ecosystem was already worth $81.04 billion last year. Whatever the case, experts project that the industry could expand at a <a href="https://www.grandviewresearch.com/industry-analysis/biomarkers-industry">compound annual growth rate of 13.36%</a> by 2030. By the forecast culmination point, it may be worth $194.21 billion.



Again, with POAI stock featuring just a morsel of the growing pie, the opportunity for speculators is immense. Still, it must also be acknowledged that Predictive represents a highly speculative investment.



Since the start of the year, POAI stock dropped more than 50% in value. That&rsquo;s inclusive of today&rsquo;s blistering run. Further, in the past 52 weeks, POAI suffered a drop of 64%. Not surprisingly, Wall Street analysts currently do not cover Predictive Oncology. Still, that might change due to the equity&rsquo;s strong performance and significant credibility boost.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-predictive-oncology-poai-stock-up-70-today/">Why Is Predictive Oncology (POAI) Stock Up 70% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Predictive Oncology (POAI) Stock Up 70% Today?

Predictive Oncology looks to raise $1.3M through exercise of warrants

Here's the major earnings before the open tomorrow

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) just reported results for the second quarter of 2024.<ul><li>Predictive Oncology reported earnings per share of -68 cents.</li><li>The company reported revenue of $278,722.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/poai-stock-earnings-predictive-oncology-for-q2-of-2024/">POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024

Predictive Oncology GAAP EPS of -$0.68, revenue of $0.28M

Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript

Predictive Oncology files to sell 1.98M shares of common stock for holders

Predictive Oncology (POAI – Research Report) received a Buy rating and a $3.00 price target from H.C. Wainwright analyst Swayampakula Ramakanth tod...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Predictive Oncology

Predictive Oncology (POAI) Forecast

Predictive Oncology (NASDAQ:POAI) Stock, Quote.Headers.trade-ideas